DUBLIN--(BUSINESS WIRE)--The "CD 3 Inhibitor -Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
'CD 3 Inhibitor - Pipeline Insight, 2018' report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across CD 3 Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:
- Clinical
- Non-clinical
- Inactive: Discontinued and/or Dormant
Descriptive coverage of pipeline development activities for CD 3 Inhibitor - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Key Topics Covered:
1. Report Introduction
2. CD 3 Inhibitor - Overview
5. CD 3 Inhibitor Pipeline Products in Clinical Stages
- Affimed Therapeutics
- MacroGenics
- Roche
- Tolerance Therapeutics
- Emergent BioSolutions
- Genentech
- MacroGenics
- NovImmune SA
- Micromet Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/3tb6ml/cd_3_inhibitor?w=4
